Vascular Endothelial Growth Factor Inhibition Shows Long-Lasting Efficacy In Treating Neovascular Age-Related Macular Degeneration: Presented At AAO

Thursday, November 13, 2008

Comments

DG News

An experimental vascular endothelial growth factor (VEGF) inhibition treatment called VEGF Trap-Eye produces at least similar results to that of the standard of care in the treatment of neovascular age-related macular degeneration (AMD), according to trial results presented here at the American Academy of Ophthalmology (AAO) annual meeting.

Full Story

The majority of vision loss in diabetic patients is due to which of the following:
1. Cataract
2. Macular edema
3. Vitreous hemorrhage
4. Tractional retinal detachment
Check The Answer

CareCloud Charts For Ophthalmology
Get all of the tools you need to deliver... view product
VISUPLAN 500 Non-Contact Tonometer
The measurement of intraocular pressure ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us

AdGlare Leaderboard

Vascular Endothelial Growth Factor Inhibition Shows Long-Lasting Efficacy In Treating Neovascular Age-Related Macular Degeneration: Presented At AAO

Comments

Quick Quiz

The majority of vision loss in diabetic patients is due to which of the following:

AdGlare RMR Ad

Featured Products

CareCloud Charts For Ophthalmology

VISUPLAN 500 Non-Contact Tonometer

Follow OphthalmologyWeb

AdGlare RMR2

Write for Us